MP33-16 PATIENT EXPERIENCE WITH IN-OFFICE TRANSPERINEAL PROSTATE BIOPSY: DOES MEDICATION MAKE A DIFFERENCE?

Le résumé fourni par la source

You have accessJournal of UrologyHealth Services Research: Quality Improvement & Patient Safety II (MP33)1 May 2024MP33-16 PATIENT EXPERIENCE WITH IN-OFFICE TRANSPERINEAL PROSTATE BIOPSY: DOES MEDICATION MAKE A DIFFERENCE? Charan S. Mohan, Michael J. Schwartz, Jay T. Bishoff, Manish Vira, and Adam I. Cole Charan S. MohanCharan S. Mohan , Michael J. SchwartzMichael J. Schwartz , Jay T. BishoffJay T. Bishoff , Manish ViraManish Vira , and Adam I. ColeAdam I. Cole View All Author Informationhttps://doi.org/10.1097/01.JU.0001009520.30626.80.16AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: The objective of this study is to examine the patient experience with in-office transperineal (TP) prostate biopsies and the impact of a single dose of diazepam on post procedural pain and discomfort. METHODS: Patients undergoing in-office TP prostate biopsy between July 2022 and June 2023 in our practice were included. A block containing 27 mL of lidocaine 1% was administered to each patient, with or without sodium bicarbonate 8.4% mixed in a 9:1 ratio. All patients were offered a single dose of diazepam 5mg to take 30 min prior to their scheduled biopsy appointment. Pain scores were assessed on a post-procedural survey consisting of four questions pertaining to overall discomfort, probe discomfort, discomfort from the biopsy, and willingness to return for future medically needed biopsies (Figure 1). Responses were grade on a 10-point Likert scale. RESULTS: 208 patients were included. The median age was 66 (IQR 61-72). 86.1% of the biopsies performed were fusion biopsies whereas the remainder were non-fusion TP biopsies. The median response with IQR for each question was as follows: Question 1: 2 (IQR 1-5), Question 2: 2 (IQR 1-5), Question 3: 2 (IQR 0-5), Question 4: 1 (IQR 0-6) (Figure 1). 81 patients (39%) opted to take the dose of periprocedural diazepam. Table 1 displays the median response to the patient survey between those patients who took diazepam and those who did not. There was no significant difference in all four measures assessed with or without diazepam. Of all patients in this series, only 7 patients responded with a 10 to Question 4, consistent with never returning for an in-office TP biopsy should a repeat biopsy be medically necessary. CONCLUSIONS: Office-based TP biopsy is overall well tolerated. Periprocedural diazepam did not have a significant impact in changing the overall patient discomfort and experience with in-office TP prostate biopsies. With over 96% of patient expressing willingness to return for further biopsies as medically needed, in-office TP prostate biopsy also represents a suitable tool to biopsy patients who need ongoing surveillance. Future studies should investigate both pharmacologic and non-pharmacologic adjuncts to improve the overall patient experience. Download PPT Source of Funding: None © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e566 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Charan S. Mohan More articles by this author Michael J. Schwartz More articles by this author Jay T. Bishoff More articles by this author Manish Vira More articles by this author Adam I. Cole More articles by this author Expand All Advertisement PDF downloadLoading ...

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.